Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia.
OBJECTIVE
Dipeptidyl peptidase 2 (DPP2/DPP7) is a regulator of quiescence as inhibition of DPP2 results in apoptosis of resting, but not activated lymphocytes. The purpose of the present study was to investigate the prognostic value of DPP2 inhibition and the role of DPP2 in cell cycle in chronic lymphocytic leukemia (CLL).


METHODS
We screened 152 peripheral blood samples from patients with CLL in an apoptosis assay with AX8819, a DPP2-specific inhibitor. The apoptotic response was correlated with B-cell receptor signaling and cell cycle and molecular prognostic factors.


RESULTS
We categorized CLL into two prognostic subgroups. Inhibition of DPP2 induced apoptosis in 60% of CLL, while 40% were resistant to apoptosis. Resistance to apoptosis correlated with unmutated IgV(H) and increased ZAP-70 expression and was associated with unfavorable clinical outcomes. Sensitive CLL B cells expressed high p27, low c-Myc protein levels and decreased Syk phosphorylation, indicative of a resting phenotype. DPP2 inhibition in those cells resulted in apoptosis accompanied by enhanced phosphorylation of Syk, degradation of p27 and p130, and upregulation of c-Myc, indicative of activation and inappropriate cell cycle entry. Resistant CLL demonstrated baseline low p27 and high c-Myc protein levels and increased pSyk, indicative of an activated phenotype. Inhibition of heat shock protein 90 in this subset of CLL partially reversed apoptosis resistance.


CONCLUSIONS
The DPP2 apoptosis assay provides a reliable prognostic factor in CLL. CLL B cells sensitive to DPP2 inhibition are in true G(0), while resistant CLL B-cells are partially activated. DPP2 inhibition alone or with concomitant inhibition of heat shock protein 90 warrants investigation as a therapeutic modality in CLL.
Danilov
Alexey V
AV
Tufts Medical Center, Department of Pathology,Tufts University School of Medicine, 150 Harrison Avenue, Boston, MA 02111, USA.
Danilova
Olga V
OV
Brown
Jennifer R
JR
Rabinowitz
Arthur
A
Klein
Andreas K
AK
Huber
Brigitte T
BT
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017209:Apoptosis; D001402:B-Lymphocytes / Q000276:immunology*; D002453:Cell Cycle; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000037:antagonists & inhibitors / Q000502:physiology*; D005260:Female; D018841:HSP90 Heat-Shock Proteins / Q000037:antagonists & inhibitors; D006801:Humans; D007143:Immunoglobulin Heavy Chains / Q000235:genetics; D007135:Immunoglobulin Variable Region / Q000235:genetics; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D034741:RNA, Small Interfering / Q000235:genetics; D051746:ZAP-70 Protein-Tyrosine Kinase / Q000032:analysis
D018841:HSP90 Heat-Shock Proteins; D007143:Immunoglobulin Heavy Chains; D007135:Immunoglobulin Variable Region; D034741:RNA, Small Interfering; D051746:ZAP-70 Protein-Tyrosine Kinase; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; C100151:dipeptidyl peptidase II
J Biol Chem. 1999 Nov 26;274(48):34053-8
10567372
J Cell Biochem. 2007 Dec 15;102(6):1400-4
17979151
Blood. 2002 Aug 15;100(4):1404-9
12149224
Cell. 1983 Dec;35(3 Pt 2):603-10
6606489
J Clin Oncol. 2007 Mar 1;25(7):799-804
17283363
Cell Cycle. 2009 Aug;8(15):2425-34
19556882
Trends Immunol. 2003 Jul;24(7):380-6
12860529
Bioorg Med Chem Lett. 2007 Jan 15;17(2):507-10
17055271
Mol Immunol. 2008 Aug;45(13):3618-23
18555530
J Biol Chem. 2002 Aug 23;277(34):31263-9
12070150
Blood. 2002 Jun 1;99(11):4087-93
12010811
Blood. 2008 Mar 1;111(5):2685-92
18048647
Blood. 1999 Sep 15;94(6):1840-7
10477712
Blood. 1998 Jun 15;91(12):4694-700
9616167
Oncogene. 2008 Apr 10;27(17):2445-55
17982489
Leuk Lymphoma. 1996 Dec;24(1-2):27-33
9049959
J Immunol. 1999 Sep 15;163(6):3092-9
10477574
Curr Opin Genet Dev. 2002 Feb;12(1):47-52
11790554
J Clin Invest. 2005 Mar;115(3):755-64
15711642
Nat Rev Immunol. 2006 Apr;6(4):283-94
16557260
Br J Haematol. 2007 Dec;139(5):837-44
17949452
Leukemia. 2004 Mar;18(3):584-8
14712292
Blood. 2002 Aug 15;100(4):1410-6
12149225
Cancer Res. 2005 Aug 15;65(16):7328-37
16103084
Blood. 2008 Sep 1;112(5):1923-30
18577710
Blood. 2005 Oct 1;106(7):2506-12
15972449
Blood. 2007 Nov 1;110(9):3352-9
17684154
Blood Rev. 2008 Jul;22(4):211-9
18448218
Blood. 2009 Jul 30;114(5):957-64
19414856
Blood. 2007 Mar 1;109(5):2032-9
17038529
J Exp Med. 2001 Dec 3;194(11):1639-47
11733578
N Engl J Med. 2004 Aug 26;351(9):893-901
15329427
Cancer Res. 2009 Jul 1;69(13):5424-32
19549911
Cancer Res. 2006 Jul 15;66(14):7158-66
16849562
Blood Rev. 1997 Sep;11(3):119-28
9370043
Blood. 2005 Mar 1;105(5):2036-41
15514014
Nat Rev Immunol. 2002 May;2(5):354-63
12033741
Br J Haematol. 2005 Feb;128(4):472-81
15686454
Cytometry B Clin Cytom. 2009 Nov;76(6):385-93
19479984
Cell. 1992 Apr 3;69(1):119-28
1555236
Blood. 1999 Sep 15;94(6):1848-54
10477713